AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash.

LSEG also reported a 78% increase in deals worth more than $10 billion during the first half of 2025, compared to 2024 levels ...

Richard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of Stemcentrx and its lung cancer drug Rova-T. Rova-T was supposed to be the cancer ...

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate ...

AbbVie to acquire Capstan Therapeutics for up to $2.1B in cash AbbVie (ABBV) agreed to acquire clinical-stage biotechnology company Capstan Therapeutics for up to $2.1 billion in cash.

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Funding to North American startups surged in the first half of 2025, fueled by investor enthusiasm around artificial ...